PT2953973T - Agentes de ligação do receptor muscarínico de acetilololina e usos - Google Patents

Agentes de ligação do receptor muscarínico de acetilololina e usos

Info

Publication number: PT2953973T
Authority: PT; Portugal
Prior art keywords: receptor binding; binding agents; acetylcholine receptor; muscarinic acetylcholine; muscarinic
Prior art date: 2013-02-05

Application number

PT147033377T

Other languages

English (en)

Inventor

Steyaert Jan

Pardon Els

Kobilka Brian

Ring Aaron

Kruse Andrew

Manglik Aasish

Original Assignee

Univ Brussel Vrije

The Board Of Trustees Of The Univ Of The Leland Stanford Junior Univ

Vib Vzw

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-02-05

Filing date

2014-02-05

Publication date

2019-10-25

2014-02-05 Application filed by Univ Brussel Vrije, The Board Of Trustees Of The Univ Of The Leland Stanford Junior Univ, Vib Vzw filed Critical Univ Brussel Vrije

2019-10-25 Publication of PT2953973T publication Critical patent/PT2953973T/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Investigating Or Analysing Biological Materials (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Apparatus Associated With Microorganisms And Enzymes (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

PT147033377T 2013-02-05 2014-02-05 Agentes de ligação do receptor muscarínico de acetilololina e usos PT2953973T (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361761136P	2013-02-05	2013-02-05
US201361961058P	2013-10-03	2013-10-03

Publications (1)

Publication Number	Publication Date
PT2953973T true PT2953973T (pt)	2019-10-25

Family

ID=50070546

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT147033377T PT2953973T (pt)	2013-02-05	2014-02-05	Agentes de ligação do receptor muscarínico de acetilololina e usos

Country Status (10)

Country	Link
US (3)	US20150368339A1 (pt)
EP (2)	EP2953973B1 (pt)
JP (2)	JP2016512954A (pt)
AU (1)	AU2014214054B2 (pt)
CA (1)	CA2900147C (pt)
DK (1)	DK2953973T3 (pt)
ES (1)	ES2745772T3 (pt)
PL (1)	PL2953973T3 (pt)
PT (1)	PT2953973T (pt)
WO (1)	WO2014122183A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201014715D0 (en)	2010-09-06	2010-10-20	Vib Vzw	Nanobodies stabilizing functional conformational states of GPCRS
GB201601690D0 (en)	2016-01-29	2016-03-16	Heptares Therapeutics Ltd	G proteins
US20180244784A1 (en) *	2017-01-05	2018-08-30	Heman Lap Man CHAO	Vegfr2 antibodies
WO2018126317A1 (en) *	2017-01-05	2018-07-12	Helix Biopharma Corporation	Vegfr-2 car immune cells to treat cancers
CN111511763B (zh)	2017-08-09	2024-05-31	奥里尼斯生物科学有限公司	Cd8结合剂
KR20200091400A (ko)	2017-10-31	2020-07-30	브이아이비 브이지더블유	신규한 항원-결합 키메라 단백질 및 이의 방법 및 용도
WO2020221769A1 (en)	2019-04-29	2020-11-05	Confo Therapeutics N.V.	Screening methods and assays for use with transmembrane proteins, in particular with gpcrs
WO2021140205A1 (en)	2020-01-10	2021-07-15	Confo Therapeutics N.V.	Methods for generating antibodies and antibody fragments and libraries comprising same

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1621554T4 (da)	1992-08-21	2012-12-17	Univ Bruxelles	Immunoglobuliner blottet for lette kæder
ES2162863T3 (es)	1993-04-29	2002-01-16	Unilever Nv	Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
FR2708622B1 (fr)	1993-08-02	1997-04-18	Raymond Hamers	Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
EP0739981A1 (en)	1995-04-25	1996-10-30	Vrije Universiteit Brussel	Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US5721121A (en)	1995-06-06	1998-02-24	Genentech, Inc.	Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
ES2294799T3 (es)	1996-06-27	2008-04-01	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw.	Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana.
AU3596599A (en)	1998-01-26	1999-08-09	Unilever Plc	Method for producing antibody fragments
EP1141711A1 (en)	1999-01-05	2001-10-10	Unilever Plc	Binding of antibody fragments to solid supports
DK1144616T4 (da)	1999-01-19	2009-03-30	Unilever Nv	Fremgangsmåde til fremstilling af antistoffragmenter
CA2370351A1 (en)	1999-04-22	2000-11-02	Unilever Plc	Inhibition of viral infection using monovalent antigen-binding proteins
US6479280B1 (en)	1999-09-24	2002-11-12	Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw	Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
ES2331051T3 (es)	1999-11-29	2009-12-21	Bac Ip B.V.	Inmovilizacion de moleculas de union de antigenos de un dominio.
WO2001040310A2 (en)	1999-11-29	2001-06-07	Unilever Plc	Immobilisation of proteins using a polypeptide segment
ES2324280T3 (es)	2000-03-14	2009-08-04	Unilever N.V.	Dominios variables de la cadena pesada de anticuerpos frente a lipasas dieteticas humanas y sus usos.
US20030190598A1 (en)	2000-05-26	2003-10-09	Jasmid Tanha	Single-domain antigen-binding antibody fragments derived from llama antibodies
ATE513854T1 (de)	2000-12-13	2011-07-15	Bac Ip B V	Proteinraster aus variablen domänen der schweren immunoglobulinkette von kamelen
GB0110029D0 (en)	2001-04-24	2001-06-13	Grosveld Frank	Transgenic animal
JP4213586B2 (ja)	2001-09-13	2009-01-21	株式会社抗体研究所	ラクダ抗体ライブラリーの作製方法
JP2005289809A (ja)	2001-10-24	2005-10-20	Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw)	突然変異重鎖抗体
EP1456237A2 (en)	2001-12-21	2004-09-15	Vlaams Interuniversitair Instituut voor Biotechnologie vzw.	Method for cloning of variable domain sequences
CA2471645A1 (en)	2002-01-03	2003-07-10	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	Immunoconjugates useful for treatment of tumours
WO2004041863A2 (en)	2002-11-08	2004-05-21	Ablynx N.V.	Single domain antibodies directed against interferon- gamma and uses therefor
EP1558645B1 (en)	2002-11-08	2011-07-27	Ablynx N.V.	Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
GB0228210D0 (en)	2002-12-03	2003-01-08	Babraham Inst	Single chain antibodies
MXPA05007151A (es)	2002-12-31	2005-09-21	Nektar Therapeutics Al Corp	Polimeros terminados en maleimida hidroliticamente estables.
JP2006517789A (ja)	2003-01-10	2006-08-03	アブリンクスエン．ヴェー．	治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
ATE485307T1 (de)	2003-11-07	2010-11-15	Ablynx Nv	Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
WO2006040153A2 (en)	2004-10-13	2006-04-20	Ablynx N.V.	Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
AU2005325801A1 (en)	2005-01-31	2006-08-03	Ablynx N.V.	Method for generating variable domain sequences of heavy chain antibodies
US8188223B2 (en)	2005-05-18	2012-05-29	Ablynx N.V.	Serum albumin binding proteins
ES2694247T3 (es)	2005-05-20	2018-12-19	Ablynx N.V.	NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
WO2008020079A1 (en)	2006-08-18	2008-02-21	Ablynx N.V.	Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
EP2121757A2 (en)	2007-02-21	2009-11-25	Ablynx N.V.	Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
CA2687903C (en)	2007-05-24	2016-09-13	Ablynx N.V.	Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
WO2010066740A1 (en)	2008-12-08	2010-06-17	Complix Nv	Single-chain antiparallel coiled coil proteins
CN102257003B (zh)	2008-12-19	2017-04-05	埃博灵克斯股份有限公司	用于产生针对细胞相关抗原如p2x7、cxcr7或cxcr4的免疫球蛋白的基因免疫
WO2011083140A1 (en)	2010-01-08	2011-07-14	Ablynx Nv	Immunoglobulin single variable domain directed against human cxcr4
GB201014715D0 (en)	2010-09-06	2010-10-20	Vib Vzw	Nanobodies stabilizing functional conformational states of GPCRS
EP2611826B1 (en)	2010-08-30	2016-09-21	Confometrx, Inc.	Method and composition for crystallizing a family c gpcr
US8765414B2 (en)	2011-03-15	2014-07-01	The Board Of Trustees Of The Leland Stanford Junior University	GPCR fusion protein containing an N-terminal autonomously folding stable domain, and crystals of the same
EA201391514A1 (ru)	2011-05-13	2014-08-29	Рецептос, Инк	Новые партнеры слияния для кристаллизации рецепторов, связанных с g-белками
CN105102478A (zh) *	2013-01-30	2015-11-25	弗拉芒区生物技术研究所	用于筛选和药物发现目的的新型嵌合多肽

2014
- 2014-02-05 US US14/765,824 patent/US20150368339A1/en not_active Abandoned
- 2014-02-05 DK DK14703337.7T patent/DK2953973T3/da active
- 2014-02-05 EP EP14703337.7A patent/EP2953973B1/en active Active
- 2014-02-05 EP EP19184955.3A patent/EP3590578A1/en not_active Withdrawn
- 2014-02-05 CA CA2900147A patent/CA2900147C/en active Active
- 2014-02-05 PL PL14703337T patent/PL2953973T3/pl unknown
- 2014-02-05 JP JP2015555753A patent/JP2016512954A/ja active Pending
- 2014-02-05 PT PT147033377T patent/PT2953973T/pt unknown
- 2014-02-05 ES ES14703337T patent/ES2745772T3/es active Active
- 2014-02-05 WO PCT/EP2014/052265 patent/WO2014122183A1/en not_active Ceased
- 2014-02-05 AU AU2014214054A patent/AU2014214054B2/en active Active
2018
- 2018-03-29 US US15/939,748 patent/US20180222978A1/en not_active Abandoned
2019
- 2019-02-22 JP JP2019030146A patent/JP6827485B2/ja active Active
2021
- 2021-07-02 US US17/366,755 patent/US20210340249A1/en active Pending

Also Published As

Publication number	Publication date
EP2953973A1 (en)	2015-12-16
US20180222978A1 (en)	2018-08-09
CA2900147C (en)	2023-09-05
US20210340249A1 (en)	2021-11-04
ES2745772T3 (es)	2020-03-03
US20150368339A1 (en)	2015-12-24
JP2016512954A (ja)	2016-05-12
PL2953973T3 (pl)	2020-01-31
WO2014122183A1 (en)	2014-08-14
JP6827485B2 (ja)	2021-02-10
CA2900147A1 (en)	2014-08-14
EP3590578A1 (en)	2020-01-08
JP2019122378A (ja)	2019-07-25
AU2014214054B2 (en)	2018-10-04
AU2014214054A1 (en)	2015-08-20
EP2953973B1 (en)	2019-07-10
WO2014122183A9 (en)	2016-05-26
DK2953973T3 (da)	2019-08-12

Publication	Publication Date	Title
ZA201500872B (en)	2016-06-29	Rspo3 binding agents and uses thereof
ZA201602501B (en)	2017-07-26	Pyrrolobenzodiazepines and conjugates thereof
IL234719A0 (en)	2014-11-30	Anti-pmel17 antibodies and immunoconjugates
IL241532B (en)	2019-11-28	Pyrrolobenzodiazepines and their conjugates
ZA201506668B (en)	2017-01-25	Pyrrolobenzodiazepines and conjugates thereof
ZA201505753B (en)	2022-03-30	Pyrrolobenzodiazepines and conjugates thereof
SG11201405881TA (en)	2014-10-30	Anti-lgr5 antibodies and immunoconjugates
SMT201900339T1 (it)	2019-07-11	Coniugati anticorpo anti-dll3/pbd e loro usi
GB201317981D0 (en)	2013-11-27	Pyrrolobenzodiazepines and conjugates thereof
IL237176A0 (en)	2015-04-30	Anticholinergic preparation that protects the nervous system and methods
IL239643A0 (en)	2015-08-31	Converted morphines and their use
IL254416A0 (en)	2017-11-30	Anti-asic1 antibodies and their uses
GB2513444B (en)	2015-03-11	Improved stopper device
PL2953973T3 (pl)	2020-01-31	Środki wiążące muskarynowy receptor acetylocholiny i ich zastosowania
PL3016520T5 (pl)	2023-07-03	kompozycje mieszanek kawowych
GB201604311D0 (en)	2016-04-27	Solids-free diverting agents and methods related thereto
GB201318151D0 (en)	2013-11-27	Composition and device
IL237400B (en)	2019-03-31	Rhizobacteria and its uses
GB201210989D0 (en)	2012-08-01	Composition and device
AU2013900167A0 (en)	2013-01-31	Alpha7 Nicotinic Acetylcholine Receptor Modulators and Uses Thereof-II
PL2641462T3 (pl)	2016-10-31	Urządzenie wiążące
GB201208372D0 (en)	2012-06-27	Antibodies and uses thereof